ABSTRACT In this study, several etodolac‐based hydrazone, thiazolidinone, and triazole derivatives that we synthesized and characterized in our earlier research were tested against the hormone‐responsive breast cell line MCF‐7 and the triple‐negative MDA‐MB‐231, as well as the murine origin fibroblast cell line L‐929, at varying doses for their effects on cell viability and toxicity and for their inhibitory activity on cyclooxygenase‐2 (COX‐2)/prostaglandin E2 (PGE2) formation. Cell viability and apoptosis tests were utilized to assess the anti‐cancer potential of etodolac and its derivatives after the cells were exposed to varied concentrations of synthesized compounds for three different time periods. ELISA and Western blot methods were used to detect protein levels. All synthesized compounds demonstrated higher anti‐cancer activity at significantly lower doses compared to etodolac (half‐maximal inhibitory concentration IC50 of 0‐50 µM range in derivatives versus 0.5−1 mM range in etodolac). Except for SGK 242, which had a major toxic effect on all cells, the chemicals SGK 206 and SGK 217 had a twice‐less impact on control murine L‐929 fibroblasts. Similar to proliferation, low concentrations of SGK 206 and SGK 217 (25−50 µM) significantly induced apoptosis in breast cancer cells but not in normal cells. Additionally, they inhibited COX‐2 protein expression at 50 µM, and SGK 206 inhibited PGE2 release more effectively than etodolac in cancer cells. The results of this study suggest that, in comparison to a healthy control group, the thiazolidinone derivative SGK 206 and the thiazolidinone derivative SGK 217 are more effective than etodolac when it comes to the breast cancer cell lines MCF‐7 and MDA‐MB‐231. SGK 206 exhibits a low IC50 value, a distinct dose–response relationship, and strong apoptotic effects, particularly on MDA‐MB‐231 cells.
Sevinç et al. (Fri,) studied this question.